Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

EndoTAG-1. MediGene.

Gunter Schuch¹

¹University Hospital Hamburg - Eppendorf, Department of Medicine - Oncology and Hematology, Martinstr 52, D-20246, Hamburg, Germany. schuch@uke.uni-hamburg.de

Current Opinion in Investigational Drugs (London, England : 2000)

|December 24, 2005

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Author Correction: First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort IKF-AIO-MOONLIGHT trial.

Nature communications·2026

Same author

First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort trial.

Nature communications·2026

Same author

Trifluridine/Tipiracil Based Chemoradiation in locally Advanced Rectal Cancer: The Phase I/II TARC Trial.

Clinical colorectal cancer·2024

Same author

Quality of life and outcome of patients with metastatic pancreatic cancer receiving first-line chemotherapy with nab-paclitaxel and gemcitabine: Real-life results from the prospective QOLIXANE trial of the Platform for Outcome, Quality of Life and Translational Research on Pancreatic Cancer registry.

International journal of cancer·2020

Same author

Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies.

Theranostics·2020

Same author

Targeting CD38-Expressing Multiple Myeloma and Burkitt Lymphoma Cells In Vitro with Nanobody-Based Chimeric Antigen Receptors (Nb-CARs).

Cells·2020

MediGene is developing EndoTAG-1, a novel paclitaxel formulation, for advanced pancreatic cancer treatment. Phase II clinical trials are currently underway to evaluate its efficacy and safety in patients.

Area of Science:

Oncology
Nanomedicine
Pharmaceutical Development

Background:

Pancreatic cancer remains a significant challenge with limited effective treatment options.
Paclitaxel is a widely used chemotherapy agent, but its delivery can be limited by toxicity and efficacy.
Novel drug delivery systems are needed to improve the therapeutic index of existing chemotherapeutics.

Purpose of the Study:

To evaluate the potential of EndoTAG-1, a novel paclitaxel formulation, for treating advanced pancreatic cancer.
To assess the safety and efficacy of EndoTAG-1 in a Phase II clinical trial setting.

Main Methods:

EndoTAG-1 is a formulation of paclitaxel encapsulated in positively charged lipid-based complexes.
Phase II clinical trials are being conducted in patients with advanced pancreatic cancer.

Related Experiment Videos

Main Results:

Clinical trial data is currently being collected and analyzed.
Preliminary findings will inform further development and potential therapeutic applications.

Conclusions:

EndoTAG-1 represents a promising targeted drug delivery approach for pancreatic cancer.
Ongoing clinical trials are crucial for establishing the therapeutic value of this novel formulation.